FGF21 was initially suggested as a therapeutic agent for diabetes [114] by the pharmaceutical giant Eli Lilly and Co. Exogenous FGF21 infusion lowers blood glucose and triglyceride concentrations and improves pancreatic beta-cell function in db/db mice [119], yet endogenous FGF21 concentrations are positively associated with a range of dysmetabolic biomarkers, including blood glucose, insulin, and c-peptide concentrations in humans [120], which may reflect FGF21 resistance or other metabolic feedback processes. The gene discussed is FGF21; the disease is diabetes mellitus.